Effectiveness and safety of anti-TNF in psoriatic arthritis patients in Brazil: a post-incorporation analysis
Abstract
Aim: Psoriatic arthritis is a chronic disease that can result in disability and decreased quality of life. Materials & methods: A prospective cohort was conducted in Brazil. Disease activity was measured by the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and Clinical Disease Activity Index (CDAI), functionality by the Health Assessment Questionnaire Disability Index (HAQ-DI) and the quality of life by the EuroQol 5D (EQ-5D). Results: In total, 122 patients were included. After 6 months, a median reduction of 2.03 in the BASDAI, 7.80 in the CDAI, 0.63 in the HAQ-DI and increase of 0.12 in the EQ-5D was observed. A good clinical response was observed in 45.5% of the patients by BASDAI and 54.5% by CDAI. Higher education and better quality of life were identified as predictors of effectiveness. The most common side effects were the infections. Conclusion: Anti-TNF-α drugs were effective and safe. The incorporation of them into the Brazilian Public Health System has provided therapeutic alternatives to the treatment of psoriatic arthritis.
Formats available
You can view the full content in the following formats:
References
Papers of special note have been highlighted as: • of interest; •• of considerable interest
1.
Mantravadi S, Ogdie A, Kraft WK. Tumor necrosis factor inhibitors in psoriatic arthritis. Expert Rev. Clin. Pharmacol. 10(8), 899–910 (2017).
2.
Ogdie A, Weiss P. The epidemiology of psoriatic arthritis. Rheum. Dis. Clin. North Am. 41(4), 545–568 (2015).
3.
Olivieri I, D'Angelo S, Palazzi C et al. Pharmacoeconomic issues in psoriatic arthritis. J. Rheumatol. Suppl. 89, 103–105 (2012).
4.
Gossec L, McGonagle D, Korotaeva T et al. Minimal disease activity as a treatment target in psoriatic arthritis: a review of the literature. J. Rheumatol. pii:jrheum.170449 (2017) (Epub ahead of print).
5.
Ramiro L, Smolen JS, Landewé R et al. Pharmacological treatment of psoriatic arthritis: a systematic literature review for the 2015 update of the EULAR recommendations for the management of psoriatic arthritis. Ann. Rheum. Dis. 75, 490–498 (2016).
6.
Coates LC, Kavanaugh A, Mease PJ et al. Group for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis Rheumatol. 68, 1060–1071 (2016).
7.
Gossec L, Smolen JS, Ramiro S et al. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann. Rheum. Dis. 75(3), 499–510 (2016).
• Describes The European League Against Rheumatism recommendations for pharmacological treatment of psoriatic arthritis (PsA), including anti-TNF drugs use.
8.
Aaltonen K, Heinonen A, Joensuu J et al. Effectiveness and drug survival of TNF-inhibitors in the treatment of psoriatic arthritis: a prospective cohort study. Semin. Arthritis Rheum. 46(6), 732–739 (2017).
•• Evaluates the effectiveness and drug survival of anti-TNF-α use in PsA patients from a Finnish perspective.
9.
Perrotta FM, Marchesoni A, Lubrano E. Minimal disease activity and remission in psoriatic arthritis patients treated with anti-TNF-α drugs. J. Rheumatol. 43(2), 350–355 (2016).
10.
Glintborg B, Østergaard M, Dreyer L et al. Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factor α therapy: results from the nationwide Danish DANBIO registry. Arthritis Rheum. 63(2), 382–390 (2011).
11.
Brasil. Ministério da Saúde. Gabinete do Ministro. Portaria nº 2981 de 26 de novembro de 2009. Aprova o Componente Especializado da Assistência Farmacêutica (2009). Anexo IV. http://bvsms.saude.gov.br/bvs/saudelegis/gm/2009/prt2981_26_11_2009_rep.html.
12.
Taylor W, Gladman D, Helliwell P et al. Classification Criteria for Psoriatic Arthritis: development of new criteria from a large international study. Arthritis Rheum. 54(8), 2665–2673 (2006).
13.
Eder L, Chandran V, Shen H, Cook RJ, Gladman DD. Is ASDAS better than BASDAI as a measure of disease activity in axial psoriatic arthritis? Ann. Rheum. Dis. 69(12), 2160–2164 (2010).
14.
Viegas Andrade M, Noronha K, Kind P et al. Societal preferences for EQ-5D health states from a Brazilian population survey. Value Health Reg. Iss. 2(3), 405–412 (2013).
15.
Ghasemi A, Zahediasl S. Normality tests for statistical analysis: a guide for non-statisticians. Int. J. Endocrinol. Metab. 10(2), 486–489 (2012).
16.
Van Buuren S, Groothuis-Oudshoorn K. Mice: multivariate imputation by chained equations in R. J. Stat. Software 45(3), (2011) (Epub ahead of print).
•• An important and very helpful paper about multiple imputation of missing data.
17.
R Core Team. R: a language and environment for statistical computing. The R Project for Statistical Computing, Vienna, Austria. www.R-project.org/.
18.
World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 310(20), 2191–2194 (2013).
19.
Mease PJ, Collier DH, Saunders KC, Li G, Kremer JM, Greenberg JD. Comparative effectiveness of biologic monotherapy versus combination therapy for patients with psoriatic arthritis: results from the Corrona registry. RMD Open 1(1), e000181 (2015).
20.
Brasil. Ministério da Saúde. Secretaria de Atenção a Saúde. Portaria Conjunta nº 6/2017 – Publicada em 19/07/2017. Aprova o Protocolo Clínico e Diretrizes Terapêuticas da Artrite Psoríaca. http://conitec.gov.br/images/Relatorios/2017/Relatório_PCDT_Artrite_Psoríaca_Secretário_nº277.pdf.
• A clinical protocol and therapeutic guideline of the PsA in Brazil.
21.
Soubrier AS, Bele-Philippe P, Cortet B et al. Treatment response, drug survival and safety of anti-tumour necrosis factor α therapy in 193 patients with psoriatic arthritis: a twelve-year ‘real life’ experience. Joint Bone Spine 82(1), 31–37 (2015).
22.
Lubrano E, Spadaro A, Marchesoni A et al. The effectiveness of a biologic agent on axial manifestations of psoriatic arthritis. A twelve months observational study in a group of patients treated with etanercept. Clin. Exp. Rheumatol. 29(1), 80–84 (2011).
23.
Cawson MR, Mitchell SA, Knight C et al. Systematic review, network meta-analysis and economic evaluation of biological therapy for the management of active psoriatic arthritis. BMC Musculoskelet. Disord. 15, 26 (2014).
24.
Scarpa R, Atteno M, Lubrano E et al. The effectiveness and safety of TNF-alpha blockers in the treatment of early psoriatic arthritis: an Italian multicentre longitudinal observational pilot study. Clin. Rheumatol. 30(8), 1063–1067 (2011).
25.
Gladman DD, Bombardier C, Thorne C et al. Effectiveness and safety of etanercept in patients with psoriatic arthritis in a Canadian clinical practice setting: the REPArE trial. J. Rheumatol. 38(7), 1355–1362 (2011).
26.
Teoli M, Zangrilli A, Chimenti MS et al. Evaluation of clinical and ultrasonographic parameters in psoriatic arthritis patients treated with adalimumab: a retrospective study. Clin. Dev. Immunol. 2012, 823854 (2012).
27.
Lemos LL, de Oliveira Costa J, Almeida AM et al. Treatment of psoriatic arthritis with anti-TNF-α agents: a systematic review and meta-analysis of efficacy, effectiveness and safety. Rheumatol. Int. 34(10), 1345–1360 (2014).
• Good systematic review of randomized controlled trials and observational studies on the efficacy, effectiveness and safety of biological disease-modifying antirheumatic drugs for PsA.
28.
Saad AA, Ashcroft DM, Watson KD et al. Efficacy and safety of anti-TNF-α therapies in psoriatic arthritis: an observational study from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) 49(4), 697–705 (2010).
29.
Fénix-Caballero S, Alegre-del Rey EJ, Castaño-Lara R et al. Direct and indirect comparison of the efficacy and safety of adalimumab, etanercept, infliximab and golimumab in psoriatic arthritis. J. Clin. Pharm. Ther. 38(4), 286–293 (2013).
30.
Carneiro S, Azevedo VF, Bonfiglioli R et al. Comissão de Espondiloartrites da Sociedade Brasileira de Reumatologia. Recommendations for the management and treatment of psoriatic arthritis. Rev. Bras. Reumatol. 53(3), 227–241 (2013).
31.
Dos Santos JB, Almeida AM, Acurcio FA et al. Comparative effectiveness of adalimumab and etanercept for rheumatoid arthritis in the Brazilian Public Health System. J. Comp. Eff. Res. 5(6), 539–549 (2016).
32.
Machado MA, Almeida AM, Kakehasi AM, Acurcio FA. Real life experience of first course of anti-TNF-α treatment in ankylosing spondylitis patients in Brazil. Rheumatol. Ther. 3(1), 143–154 (2016).
33.
Mease PJ, Kavanaugh A, Coates LC et al. Prediction and benefits of minimal disease activity in patients with psoriatic arthritis and active skin disease in the ADEPT trial. RMD Open 3(1), e000415 (2017).
34.
Smolen JS, Schöls M, Braun J et al. Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. Ann. Rheum. Dis. 77(1), 3–17 (2018).
•• Shows the importance of treat-to-target adopted as a reference for minimal disease activity and remission applied the PsA. A systematic review and recommendations.
35.
Mease PJ, Armstrong AW. Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis. Drugs 74(4), 423–441 (2014).
36.
Carneiro C, Chaves M, Verardino G et al. Evaluation of fatigue and its correlation with quality of life index, anxiety symptoms, depression and activity of disease in patients with psoriatic arthritis. Clin. Cosmet. Investig. Dermatol. 10, 155–163 (2017).
37.
Matcham F, Scott IC, Rayner L et al. The impact of rheumatoid arthritis on quality-of-life assessed using the SF-36: a systematic review and meta-analysis. Semin. Arthritis Rheum. 44(2), 123–130 (2014).
38.
Tillett W, de-Vries C, McHugh NJ. Work disability in psoriatic arthritis: a systematic review. Rheumatology (Oxford) 51(2), 275–283 (2012).
39.
Minozzi S, Bonovas S, Lytras T et al. Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis. Expert Opin. Drug Saf. 15(Suppl. 1), 11–34 (2016).
40.
Garcia-Doval I, Carretero G, Vanaclocha F et al. Risk of serious adverse events associated with biologic and nonbiologic psoriasis systemic therapy: patients ineligible vs eligible for randomized controlled trials. Arch. Dermatol. 148(4), 463–470 (2012).
41.
Warren RB, Smith CH, Yiu ZZN et al. Differential drug survival of biologic therapies for the treatment of psoriasis: a prospective observational cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). J. Invest. Dermatol. 135(11), 2632–2640 (2015).
42.
Goldfien RD, Ng MS, Yip G et al. Effectiveness of a pharmacist-based gout care management programme in a large integrated health plan: results from a pilot study. BMJ Open 4(1), e003627 (2014).
43.
Marra CA, Grubisic M, Cibere J et al. Cost-utility analysis of a multidisciplinary strategy to manage osteoarthritis of the knee: economic evaluation of a cluster randomized controlled trial study. Arthritis Care Res. (Hoboken) 66(6), 810–816 (2014).
44.
O'Dwyer JL, Meads DM, Hulme CT et al. The cost–effectiveness of tight control of inflammation in early psoriatic arthritis: economic analysis of the TICOPA trial. Arthritis Care Res. (Hoboken) 70(3), 462–468 (2018).
Information & Authors
Information
Published In
Copyright
© 2018 Future Medicine Ltd.
History
Received: 16 February 2018
Accepted: 5 July 2018
Published online: 2 October 2018
Keywords:
Topics
Authors
Metrics & Citations
Metrics
Article Usage
Article usage data only available from February 2023. Historical article usage data, showing the number of article downloads, is available upon request.
Citations
How to Cite
Effectiveness and safety of anti-TNF in psoriatic arthritis patients in Brazil: a post-incorporation analysis. (2018) Journal of Comparative Effectiveness Research. DOI: 10.2217/cer-2018-0017
Export citation
Select the citation format you wish to export for this article or chapter.
Citing Literature
- Wilson Bautista-Molano, Linda Ibatá, Susan Martínez, Andrea Chacón, Burden of Disease in Psoriatic Arthritis in Latin America: a Systematic Literature Review , Clinical Rheumatology, 10.1007/s10067-023-06838-8, 43, 2, (677-693), (2023).
- Melanie Aureal, Milene Seauve, Soline Laplane, Jean-Christophe Lega, Natalia Cabrera, Fabienne Coury, Incidence of infections in patients with psoriatic arthritis and axial spondyloarthritis treated with biological or targeted disease-modifying agents: a systematic review and meta-analysis of randomised controlled trials, open-label studies and observational studies, RMD Open, 10.1136/rmdopen-2023-003064, 9, 3, (e003064), (2023).
- Felipe A. Moraes, Michael R.R. da Silva, Jéssica B.R. dos Santos, Francisco A. Acurcio, Alessandra M. Almeida, Adriana M. Kakehasi, Juliana Alvares-Teodoro, Health-Related Quality of Life in Psoriatic Arthritis: Findings and Implications, Value in Health Regional Issues, 10.1016/j.vhri.2021.06.003, 26, (135-141), (2021).
- Michael Ruberson Ribeiro da Silva, Jéssica Barreto Ribeiro Dos Santos, Alessandra Maciel Almeida, Juliana Alvares-Teodoro, Francisco De Assis Acurcio, Economic evaluation of adalimumab versus etanercept for psoriatic arthritis in a Brazilian real-world model, Expert Review of Pharmacoeconomics & Outcomes Research, 10.1080/14737167.2021.1880325, 22, 3, (473-479), (2021).
- Isabella de Figueiredo Zuppo, Cristina Mariano Ruas, Helian Nunes de Oliveira, Brian Godman, Saulo Castel, Milton L. Wainberg, Edna Afonso Reis, Health equity and the usage of atypical antipsychotics within the Brazilian national health system: findings and implications, Expert Review of Pharmacoeconomics & Outcomes Research, 10.1080/14737167.2020.1804873, 21, 4, (743-751), (2020).
- Michael Ruberson Ribeiro da Silva, Jéssica Barreto Ribeiro dos Santos, Alessandra Maciel Almeida, Juliana Alvares-Teodoro, Adriana Maria Kakehasi, Francisco de Assis Acurcio, Access to high-cost medications for psoriatic arthritis in the National Health System in Brazil: the long path up to dispensation, Advances in Rheumatology, 10.1186/s42358-019-0091-7, 59, 1, (2019).
- Michael Ruberson Ribeiro da Silva, Jéssica Barreto Ribeiro dos Santos, Alessandra Maciel Almeida, Augusto Afonso Guerra Júnior, Juliana Alvares Teodoro, Francisco de Assis Acurcio, Biological therapy in the treatment of psoriatic arthritis: economic and epidemiological considerations, Expert Review of Clinical Immunology, 10.1080/1744666X.2019.1631798, 15, 8, (879-887), (2019).
- Michael Ruberson Ribeiro da Silva, Jéssica Barreto Ribeiro dos Santos, Alessandra Maciel Almeida, Alexander Itria, Adriana Maria Kakehasi, Juliana Alvares Teodoro, Francisco de Assis Acurcio, Medication Persistence for Psoriatic Arthritis in a Brazilian Real-World Setting, Future Science OA, 10.4155/fsoa-2018-0101, 5, 2, (2019).